Type 1 diabetes. Type 1 diabetes mellitus
Conditions
Interventions
Intervention 1: The intervention group will include 20 type 1 diabetic patients referred to the Endocrine Clinic of Amir-Al-Monin Hospital in Semnan who will receive magnesium hydroxide sachet 300 (Ro
Sponsors
Semnan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: Age between 2 and 18 years Confirmed diagnosis of type 1 diabetes mellitus Provision of informed consent to participate in the study (by the patient or legal guardian) No current use of medications or supplements containing magnesium
Exclusion criteria
Exclusion criteria: History of renal failure Presence of gastrointestinal disorders History of hyperparathyroidism or primary aldosteronism History of acute or chronic diarrhea History of gastrointestinal bypass surgery or bowel resection Use of diuretics, aminoglycosides, magnesium-containing antacids, or amphotericin B
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycemic index. Timepoint: Start of intervention and end of intervention. Method of measurement: Calculated index based on fasting plasma glucose and fasting insulin levels. | — |
Secondary
| Measure | Time frame |
|---|---|
| Height. Timepoint: Start of intervention and end of intervention. Method of measurement: Stadiometer.;Weight. Timepoint: Start of intervention and end of intervention. Method of measurement: Digital weight scale.;Blood pressure. Timepoint: Start of intervention and end of intervention. Method of measurement: Digital blood pressure monitor.;HDL-C (high-density lipoprotein). Timepoint: Start of intervention and end of intervention. Method of measurement: Enzymatic colorimetric assay using automated biochemistry analyzer.;TG (triglycerides). Timepoint: Start of intervention and end of intervention. Method of measurement: Enzymatic colorimetric assay using automated biochemistry analyzer.;VLDL (very low-density lipoprotein). Timepoint: Start of intervention and end of intervention. Method of measurement: Enzymatic colorimetric assay using automated biochemistry analyzer.;LDL (low-density lipoprotein). Timepoint: Start of intervention and end of intervention. Method of measurement: Enzymatic colorimetric assay using automated biochemistry analyzer.;Fasting plasma glucose (FPG). Timepoint: Start of intervention and end of intervention. Method of measurement: Enzymatic colorimetric assay using automated biochemistry analyzer.;Fasting blood insulin. Timepoint: Start of intervention and end of intervention. Method of measurement: Enzymatic colorimetric assay using automated biochemistry analyzer.;Insulin sensitivity indices including (quantitative insulin sensitivity) QUICKI. Timepoint: Start of intervention and end of intervention. Method of measurement: Calculated index based on fasting plasma glucose and fasting insulin levels.;HOMA-IR (assessment of insulin resistance Homeostasis model). Timepoint: Start of intervention and end of intervention. Method of measurement: Calculated index based on fasting plasma glucose and fasting insulin levels. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzane Vafaeeyan
Semnan University of Medical Sciences
Outcome results
None listed